Phase 1b trial in eosinophilic esophagitis
Latest Information Update: 01 Dec 2025
At a glance
- Drugs ANB-033 (Primary)
- Indications Eosinophilic oesophagitis
- Focus Adverse reactions
Most Recent Events
- 01 Dec 2025 New trial record
- 04 Nov 2025 According to the Anaptys media release, company plan to initiate an additional Phase 1b trial in a second inflammatory disease in 2026 in eosinophilic esophagitis as a potential indication